Bernstein analyst Bruno Monteyne downgraded Reckitt Benckiser (RBGLY) to Market Perform from Outperform with a price target of 5,300 GBp, down from 6,000 GBp. The firm sees a narrowed necrotizing enterocolitis litigigatiun valuation discount for the shares following Friday’s rally.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RBGLY:
- Abbott, Mead Johnson secure win in infant formula trial, Reuters reports
- Reckitt Benckiser price target lowered to 5,177 GBp from 5,200 GBp at Berenberg
- Reckitt Benckiser price target lowered to 5,780 GBp from 5,850 GBp at Barclays
- Reckitt Benckiser price target raised to 4,600 GBp at Morgan Stanley
- Reckitt Benckiser price target raised to 5,850 GBp from 5,815 GBp at Barclays